Genetic Testing Company | The DNA Diagnostic Experts | GeneDx

In observance of Labor Day, GeneDx will be closed and will not accept specimens on Monday, September 7, 2015.  We will resume our normal schedule on Tuesday, September 8, 2015.  If you have any questions or inquiries, please call us at 301-519-2100 or email us at

TP53 Gene Sequencing



Clinical Utility:
  • Confirmation of a clinical diagnosis
  • Differentiation between hereditary breast and ovarian cancer syndrome (BRCA1, BRCA2 genes)
  • Identification of family members at-risk to develop cancers related to LFS
  • To determine an appropriate surveillance and treatment protocol
  • Prenatal diagnosis in families with a known mutation
Lab Method:
Capillary Sequencing


Test Code:
Turnaround Time:
4-5 weeks
Preferred Specimen:
2-5 mL Blood - Lavender Top Tube
Alternative Specimen:
Oral Rinse (30-40 mL), Dried Blood Spots


CPT Codes:
New York Approved:
ABN Required:
Billing Information:
View Billing Policy
ICD Codes:
  • 194: Malignant neoplasm of other endocrine glands and related structures Excludes: islets of Langerhans (157.4) neuroendocrine tumors (209.00-209.69) ovary (183.0) testis (186.0-186.9) thymus (164.0)
  • 174: Malignant neoplasm of female breast Includes: breast (female) connective tissue soft parts
  • 191: Malignant neoplasm of brain Excludes: cranial nerves (192.0) retrobulbar area (190.1)
  • 171: Malignant neoplasm of connective and other soft tissue Includes: blood vessel bursa fascia fat ligament, except uterine muscle peripheral, sympathetic, and parasympathetic nerves and ganglia synovia tendon (sheath) Excludes: cartilage (of): articular (170.0-170.9) larynx (161.3) nose (160.0) connective tissue: breast (174.0-175.9) internal organs code to malignant neoplasm of the site [e.g., leiomyosarcoma of stomach, 151.9] heart (164.1) uterine ligament (183.4)
* For price inquiries please email


  1. Birch et al., (1994) Cancer Res 54 :1298-1304.
  2. Bougeard et al., (2003) Oncogene 22:840-846.
  3. Eeles et al., (1995) Cancer Surv 25 :101-124.
  4. Ginsburg et al., (2009) Fam Cancer 8:563-567.
  5. Gonzalez et al., (2009) J Clin Oncol 27:1250-1256.
  6. Gonzalez et al., (2009) J Med Genet 46 :689-693.
  7. Li et al., (1988) Cancer Res 48:5358-5362.
  8. Tinat et al., (2009) J Clin Oncol 27(26):e108-e109.
  9. Varley et al., (2003) Hum Mutat 21:313-320.

Back To Top